337 results
P
Hepatocellular carcinomas (HCCs), non-HCC malignancies
I/C
Contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System category M (LR-M), CEUS LR-M category, Non-HCC malignancies
O
Proportion of CEUS LR-M in HCC and non-HCC malignancies, Frequency of individual CEUS LR-M imaging features
P
patients with autoimmune diseases (ADs), healthy controls
I/C
circulating VEGF levels, comparisons of circulating VEGF levels between patients with ADs and healthy controls
O
association between circulating VEGF levels and ADs, prediction of disease manifestations, severity and activity in patients with ADs
P
MCI, AD, cognitively normal controls
I/C
MCI vs. cognitively normal controls, AD vs. cognitively normal controls
O
plasma fatty acid dysregulation, lower levels of docosahexaenoic (DHA) and vaccenic acids in MCI, 27.2% lower total fatty acids in AD, changes in plasma/serum fatty acids in both MCI and AD
P
persons with Alzheimer's disease (AD), controls
I/C
cerebrospinal fluid orexin in persons with AD and controls
O
non-significant increases in orexin were observed in AD relative to controls, with moderate to large heterogeneity among studies
P
lung cancer patients
I/C
antidepressants (AD), no ADs
O
reduced lung cancer risk
P
Listeria monocytogenes meningitis (LMM)
I/C
adjunctive dexamethasone (AD), no AD
O
mortality
P
patients with liver lesions
I/C
LI-RADS algorithm, original studies reporting probability of LR-M for HCC and non-HCC malignancy on MRI
O
pooled percentages of HCC and non-HCC malignancy for LR-M, sources of heterogeneity between reported results
P
1,356 participants (664 with AD and 692 CN individuals)
I/C
systematic review and meta-analysis, AD and cognitively normal (CN) groups
O
changes in tryptophan and kynurenine pathway metabolites
P
Women's Health Initiative
I/C
added sugar, SSB, ASB, CVD risk
O
total CVD, CHD, stroke, coronary revascularization, incident heart failure
P
Lewy body disease (LBD), Alzheimer's disease (AD), frontotemporal lobar degeneration (FTLD), healthy elderly individuals
I/C
orexin-A levels in cerebrospinal fluid (CSF), patients with LBD vs. patients with AD, patients with LBD vs. patients with FTLD, LBD patients with excessive daytime sleepiness (EDS) vs. healthy elderly individuals
O
mean orexin-A CSF levels, standard mean difference (SMD), 95% confidence interval (CI), Z-score, P-value